肠道微生物与炎症性肠病靶标发现和检测  

Discovery and Detection of Gut Microbiota and Inflammatory Bowel Disease Targets

作　　者：郑雪松 张小飞 董碟 ZHENG Xuesong;ZHANG Xiaofei;DONG Die(Wuhan Bioswamp Biotechnology Co.,Ltd..Wuhan 430000,China)

机构地区：[1]武汉贝茵莱生物科技有限公司,湖北武汉430000

出　　处：《工业微生物》2024年第1期137-139,共3页Industrial Microbiology

摘　　要：本研究旨在揭示肠道微生物与炎症性肠病(Inflammatory Bowel Disease,IBD)之间的关系,并寻找新的检测方法和治疗靶标。研究使用C57BL/6小鼠作为实验模型,建立急性结肠炎模型,并对小鼠采用不同的治疗方式,包括Hydrostatin-SN10、英夫利昔单抗(IFX),以及Hydrostatin-SN10突变肽。每日观察各组小鼠并记录相关数据。结果显示,实验组及治疗组小鼠体重均下降,葡聚糖硫酸钠盐实验组的小鼠体重下降最多,第7天小鼠体重为15.4±0.2 g,实验组小鼠结肠中糜蛋白酶C(Chymotrypsin C)、Rho-GDP解离抑制因子2(Rho GDI2)及凝溶胶蛋白(Gelsolin)表达水平显著上升,治疗组出现不同程度的下降。研究为理解肠道微生物与炎症性肠病的关系,以及炎症标志物与IBD诊断和治疗的可能关联提供了新的视角和实验数据。The research aims to reveal the relationship between gut microbiota and Inflammatory Bowel Disease(IBD),and to search for new detection methods and therapeutic targets.The study used C57BL/6 mice as experimental models to establish an acute colitis model,and different treatment methods were used for the mice,including Hydrostatin-SN10,infliximab(IFX),and Hydrostatin-SN10 mutant peptide.The paper observed and record relevant data daily for each group of mice.Both the experimental and treatment groups showed weight loss,with the DSS experimental group showing the greatest weight loss.On the 7th day,the weight of the mice was 15.4±0.2 g,the levels of Chymotrypsin C,RhoGDI2 and Gelsolin in the colon of mice in the experimental group were significantly increased,while those in the treatment group were decreased.The study provides new perspectives and experimental data to understand the relationship between gut microbiota and inflammatory bowel disease,as well as the possible association between Hydrostatin-SN10 and the treatment of IBD.

关 键 词：肠道微生物 炎症性肠病 Hydrostatin-SN10 TNFR1 C57BL/6小鼠 

分 类 号：R574[医药卫生—消化系统]